Paper Search Console

Home Search Page Alphabetical List About Contact

Journal Title

Title of Journal: J Neurooncol

Search In Journal Title:

Abbravation: Journal of Neuro-Oncology

Search In Journal Abbravation:


Springer US

Search In Publisher:



Search In DOI:



Search In ISSN:
Search In Title Of Papers:

Clear cell Meningioma, an uncommon variant of meningioma: a clinicopathologic study of nine cases

Authors: D. Jain, M. C. Sharma, C. Sarkar, V. Suri, A. Garg, M. Singh, B. S. Sharma, A. K. Mahapatra,

Publish Date: 2006/09/06
Volume: 81, Issue:3, Pages: 315-321
PDF Link


Clear cell meningioma (CCM) is an uncommon variant of meningioma, which affect younger patients, occur more often in spinal or cerebello pontine locations and shows a higher recurrence rate. Only few case reports have been described in the literature. The study has been undertaken to document the clinicopathological features of nine cases of CCM, operated at All India Institute of Medical Sciences during 1998 to December 2005.Clinical information was retrieved from the records of our Neurosurgery Department. The cases were stained with H&E, periodic Acid Schiff (PAS) with and without diastase. Immunohistochemistry for pancytokeratin, epithelial membrane antigen, vimentin, glial fibrillary acidic protein, and MIB-1 was done in all cases.During a period of 8 years, nine cases of CCM were diagnosed. Age ranged from 10 to 65 years (median age 26.0 years) with female predominance. Most common location was posterior fossa (CP angle). Clinically most of the patients presented with history of headache and features of cranial nerve palsies. The duration of symptoms varied from 3 to 60 months (mean 16.7 and median of 4 months). Radiologically lesions showed homogenous enhancement and were isointense to brain parenchyma. Histopathologic examination revealed tumor cells to be arranged in sheets with clear cytoplasm and monomorphic nuclei. MIB-1 labeling index (LI) ranged from 2 to 12% with a mean of 9%. Follow up varied from 3 to 84 months (median 36 months) and recurrence was noted in two patients after 2 and 3 years of surgery, respectively, despite their low MIB-1 labeling indices.CCM is a rare variant of meningioma with poor outcome. Less than 50 cases have been described in the literature. Low rate of recurrence and recurrence despite their low MIB-1 LI are some of the features, which needs to be documented. Hence, larger number of cases with adequate follow-up data need to be studied further to establish the clinical significance of this variant.



Search In Abstract Of Papers:
Other Papers In This Journal:

  1. Matrix metalloproteinase-1 expression enhances tumorigenicity as well as tumor-related angiogenesis and is inversely associated with TIMP-4 expression in a model of glioblastoma
  2. The effect of valproic acid in combination with irradiation and temozolomide on primary human glioblastoma cells
  3. Origins and clinical implications of the brain tumor stem cell hypothesis
  4. Genomic predictors of patterns of progression in glioblastoma and possible influences on radiation field design
  5. Suggested response criteria for phase II antitumor drug studies for neurofibromatosis type 2 related vestibular schwannoma
  6. Phase II trial of temozolomide in children with recurrent high-grade glioma
  7. Management of patients with recurrence of diffuse low grade glioma
  8. Valproic acid affected the survival and invasiveness of human glioma cells through diverse mechanisms
  9. Cognitive outcome as part and parcel of clinical outcome in brain tumor surgery
  10. The diagnostic accuracy of multiparametric MRI to determine pediatric brain tumor grades and types
  11. Do perfusion and diffusion MRI predict glioblastoma relapse sites following chemoradiation?
  12. Extraneural metastatic medulloblastoma in an adult
  13. Application of diffusion-weighted magnetic resonance imaging to predict the intracranial metastatic tumor response to gamma knife radiosurgery
  14. Tissue thioredoxin reductase-1 expression in astrocytomas of different grades
  15. Disparities in receipt of modern concurrent chemoradiotherapy in glioblastoma
  16. Multiple paraneoplastic diseases occurring in the same patient after thymomectomy
  17. Age alone is not a predictor for survival in glioblastoma

Search Result:

Help video to use 'Paper Search Console'